Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum A Injections for Pain in Rotator Cuff Arthropathy
NCT02512536Phase 2
Key facts
- Status
- Completed
- Start
- Jul 2016
- Primary completion
- Nov 2017
- Countries
- 1
- Sponsor
- Royal Devon University Healthcare NHS Foundation Trust
- Modality
- Recombinant Proteins and Enzymes
- Conditions
- rotator cuff tear arthropathy (CTA)
01
Overview
Phase 2, open-label, single-arm trial of botulinum toxin type A in rotator cuff tear arthropathy (CTA), sponsored by Royal Devon University Healthcare NHS Foundation Trust. Primary endpoint: Oxford Shoulder Score at 6 months. Started Jul 2016; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Experimental
Single ultrasound-guided injection of Botulinum Toxin Type A (Dysport)
03
Who it enrols
Patients medically fit for operation with symptomatic rotator cuff arthropathy confirmed on radiographs.
04
Endpoints
Primary
Oxford Shoulder Score
Secondary
Pain Score
Beyond the preview
Go deeper on NCT02512536.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02512536.